PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril (PRIDE)

Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/PerindopRil In Patients With Previous Myocardial Infraction With Arterial Hypertension in the Daily Clinical practicE

This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug for 12 weeks in the daily clinical practice. SPC will be used according to the approved instruction for medical use of the medicine.

This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.

Study Overview

• Status: Completed
• Conditions: Myocardial Infarction; Coronary Artery Disease; Arterial Hypertension
• Intervention / Treatment: Drug: in daily everyday routine practice

Detailed Description

This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.

Baseline data will be collected retrospectively from medical records of stable CAD patients with HTN and a history of MI, including disease history of the patient. To be included in the study for further prospective observation a patient should have been administered bisoprolol/ perindopril SPC within first three months before the Index Date. (Fig.1). Therefore, criteria for non-inclusion or inclusion of the patient in the study are to be retrospectively evaluated by the investigator using recorded clinical data available from medical records. Once a physician makes decision to include a patient in the study and, in particular, on the prospective observation for 3 months, a visit to the clinic for obtaining signed patient's consent to participate in the study should be appointed and made within 1 month from the Index Date.

Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program. Such studies are carried out in case of observational programs when the studied drug is administered in line with indications according to the instruction for its medical use.

Several multicenter, non-interventional, open, incomparable studies have been performed with bisoprolol/perindopril SPC in patients with HTN and coronary heart disease. A total of 70 general practitioners and cardiologists from primary care facilities will participate in the program. Each doctor will include about 7-8 patients. In total, it is planned to include at least 500 patients.

• Study Type: Observational
• Enrollment (Actual): 504

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation
    • Peoples' Friendship University of Russia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

CAD patients with previous MI and HTN

Description

Inclusion Criteria:

• Patients with stable angina pectoris of class I-III according to the Canadian Cardiovascular Society (CCS) classification and a history of myocardial infarction no earlier (not less) than 3 months before inclusion in the study.

HTN (including resistant* hypertension)

• Signed informed consent to participate in the study.
• Bisoprolol/ perindopril SPC prescription** within 3 month period before Index date

Exclusion Criteria:

• Hypersensitivity to bisoprolol, perindopril, excipients of the medicine, or other ACE inhibitors.
• Any contraindication for bisoprolol/perindopril's SPC according to the instruction for medical use
• CAD, angina pectoris of functional class IV according to the CCS classification (Appendix 1).
• Chronic heart failure of class III-IV according to the New York Heart Association (NYHA) functional classification of heart failure (Appendix 3).
• Cerebrovascular diseases (ischemic, haemorrhagic stroke, or transient ischemic attack) within the past 6 months prior to inclusion in the study.
• A history of revascularization procedure within 3 months prior to inclusion in the study.
• Hypertrophic obstructive cardiomyopathy.
• Office BP ≥ 180/110 mm Hg on treatment
• Type 1 diabetes mellitus and decompensated type 2 diabetes mellitus.
• Bradycardia with a heart rate of less than 60 beats per minute.
• Atrioventricular block (II-III degree), sinoatrial block, or sick sinus syndrome.
• Severe bronchial asthma or severe chronic obstructive pulmonary disease.
• Arterial hypotension (BP less than 100/70 mm Hg).
• Pregnancy, breastfeeding.
• Secondary hypertension.
• Severe decompensated diseases of organs and systems requiring continuous treatment.
• Current participation in another clinical trial and within 30 days prior to signing informed consent.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antihypertensive Effectiveness (SBP and DBP) of Bisoprolol/Perindopril SPC in CAD Patients With Previous MI and HTN at Week 12 of Treatment Compared With Baseline	Change in the mean systolic and diastolic BP levels at week 12 of treatment with SPC compared with baseline among patients included in the study.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Mean Systolic and Diastolic BP Levels at Week 4 Compared With Baseline.	Change in mean systolic and diastolic BP levels at week 4 of treatment with SPC compared with baseline.	1 month
Change in Number of Angina Attacks Per Week at Week 4 Compared With Baseline.	Change in number of angina attacks per week at week 4 of treatment compared with baseline.	1 month
Change in Number of Angina Attacks Per Week at Week 12 Compared With Baseline	Change in number of angina attacks per week at week 12 of treatment compared with baseline.	3 months
Proportion of Patients Who Were Taking Lipid Lowering Therapy	Proportion of patients who were taking lipid lowering therapy (LLT) at week 12 of treatment	3 months
SBP ≤140 mm Hg and DBP ≤90 mm Hg at Week 4 Compared With Baseline	Proportion of patients who achieved SBP ≤140 mm Hg and DBP ≤90 mm Hg at week 4.	1 month
SBP ≤140 mm Hg and DBP ≤90 mm Hg at Week 12 Compared With Baseline	Proportion of patients who achieved SBP ≤140 mm Hg and DBP ≤90 mm Hg at week 12	3 months
Younger Than 65 Who Achieved SBP ≤130 mm Hg and DBP ≤80 mm Hg at Week 4 of Treatment Compared With Baseline	Proportion of patients younger than 65 who achieved SBP ≤130 mm Hg and DBP ≤80 mm Hg at week 4 of treatment	1 month
Younger Than 65 Who Achieved SBP ≤130 mm Hg and DBP ≤80 mm Hg at Week 12 of Treatment	Proportion of patients younger than 65 who achieved SBP ≤130 mm Hg and DBP ≤80 mm Hg at week 12 of treatment.	3 months
Older Than 65 Years Who Achieved SBP≤140 mm Hg and DBP ≤90 mm Hg at Week 4 of Treatment	Proportion of patients older than 65 years who achieved SBP≤140 mm Hg and DBP ≤90 mm Hg at week 4 of treatment	1 month
Older Than 65 Years Who Achieved SBP≤140 mm Hg and DBP ≤90 mm Hg at Week 12 of Treatment	Proportion of patients older than 65 years who achieved SBP≤140 mm Hg and DBP ≤90 mm Hg at week 12 of treatment	3 months
Mean Heart Rate (HR) at Week 4 Compared With Baseline.	Changes in the mean heart rate (HR) at week 4 of treatment compared with baseline	1 month
Mean Heart Rate (HR) at Week 12 Compared With Baseline.	Changes in the mean heart rate (HR) at week 12 of treatment compared with baseline	3 months
Patients Who Achieved Target Level of Resting HR (55-60 Bpm) at Week 4	Proportion of patients who achieved target level of resting HR (55-60 bpm) at week 4 of treatment.	1 month
Patients Who Achieved Target Level of Resting HR (55-60 Bpm) at Week 12	Proportion of patients who achieved target level of resting HR (55-60 bpm) at week 12 of treatment.	3 months

Collaborators and Investigators

• Sponsor: Servier Russia
• Investigators: Principal Investigator: Zhanna Kobalava, Professor

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2021
• Primary Completion (Actual): October 5, 2021
• Study Completion (Actual): October 18, 2021

Study Registration Dates

• First Submitted: November 30, 2020
• First Submitted That Met QC Criteria: December 4, 2020
• First Posted (Actual): December 7, 2020

Study Record Updates

• Last Update Posted (Estimated): November 1, 2024
• Last Update Submitted That Met QC Criteria: August 15, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Necrosis; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Myocardial Ischemia; Ischemia; Hypertension; Coronary Artery Disease; Myocardial Infarction; Infarction
• Other Study ID Numbers: IC4-05150-065-RUS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No